Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001346824-25-000045
Filing Date
2025-11-07
Accepted
2025-11-07 16:59:24
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16036
  Complete submission text file 0001346824-25-000045.txt   17802
Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Subject) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94871 | Film No.: 251463425
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)